Development and implementation of standardized method for detecting immunogenicity of acellular pertussis vaccines in Korea.
- Author:
Chulmin PARK
1
;
Dong Ho HUH
;
Seung Beom HAN
;
Gi Sub CHOI
;
Kyu Ri KANG
;
Ji Ahn KIM
;
Jin Han KANG
Author Information
- Publication Type:Original Article
- Keywords: Pertussis vaccine; Pertussis toxin; FHA protein; Pertactin; Enzyme-linked immunosorbent assay; Serology
- MeSH: Diphtheria; Enzyme-Linked Immunosorbent Assay; Hemagglutinins; Immunoassay; Immunoglobulin G; Korea*; Methods*; Pertussis Toxin; Pertussis Vaccine; Vaccination; Vaccines*; Whooping Cough*; World Health Organization
- From:Clinical and Experimental Vaccine Research 2019;8(1):35-42
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: There is no standard method for confirming the immunogenicity of acellular pertussis vaccines. We tried to develop a local standard method for evaluating the immunogenicity of the three-component of acellular pertussis vaccines which was developed by a Korean local company. MATERIALS AND METHODS: The developed pertussis antigens (pertussis toxin, filamentous hemagglutinin, pertactin) were evaluated by in-house enzyme-linked immunosorbent assay (ELISA) using 189 negative sera, 25 positive sera, and 73 paired sera (pre- and post-Tdap [tetanus, diphtheria, and acellular pertussis] vaccinated sera). ELISA units were calculated by the reference line method, compared with World Health Organization reference sera, and the cut-off value was calculated using negative sera. RESULTS: When compared to National Institute for Biological Standards and Control control antigen (NIBSC) control antigens, the developed pertussis toxin (PT) and filamentous haemagglutinin (FHA) antigens were 203.48 and 61.60 IU/µg, respectively. Each in-house ELISA was established by validating the coefficients of variation % (PT, 11.53%; FHA, 8.60%; pertactin [PRN], 9.86%) obtained from the results of inter- and intra-assay variation. Also, the cut-off values of PT, FHA, and PRN were 11.65, 38.95, and 5.66 EU/mL, respectively. The distributions of antibody levels in paired showed that 93.15% (68/73) in anti-PT IgG, 97.26% (72/73) in anti-FHA IgG, and 100% in anti-PRN IgG were higher than a 100% increase after vaccination. Additionally, the values of 89.04% (65/73) in anti-PT IgG, 97.26% (72/73) in anti-FHA IgG, and 100% in anti-PRN IgG were below each cut-off point. CONCLUSION: We established an in-house ELISA method using self-developed antigens, and these immunoassays have provided a way to standardize measuring the immunogenicity of newly developed vaccines, through single- and dual-serology.
